This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Shelli Avenevoli, Ph.D., the deputy director for the National Institute of Mental Health (NIMH), joined Cheddar to discuss concerns about the devastating impact the pandemic has had on the nation's youth. While mental health issues have been a point of concern for the populace at large, Avenevoli talked about how vulnerable young people have been during the COVID-19 crisis. "It's important to keep in mind, for children and adolescents, that the pandemic is occurring during a time of very formative development when social connection is vital for health and optimal function," she said. Avenevoli also noted broad political and social upheavals that have contributed to the issue but also things that can be done to help minors with their mental wellbeing.
Cheddar Innovates gets a look at the satellite that's searching for the earliest light from the big bang, plus a former Nike executive breaks down what the new era of sportswear looks like.
A packed Thursday pod: Carlo and Baker cover the latest developments in the Ghislaine Maxwell, Jussie Smollett and Elizabeth Holmes trials. Plus, Dems are losing the Hispanic vote, Boris Johnson in trouble again, and is it possible that Adele has peaked?
Adam Mosseri, head of Instagram, faced withering questions on Capitol Hill about the reports the social media app was aware of the severe mental health impacts it was having on teenage girls. Karen Kornbluh, the director of digital innovation and democracy for the German Marshall Fund, joined Cheddar to discuss the rare show of bipartisan outrage on display at the Senate hearing. "The senators came really loaded for bear on both sides of the aisle," she said. Kornbluh explained how senators like Richard Blumenthal (D-Conn.) set up fake Instagram accounts with teen girl profiles in order to research the effects firsthand.
A mental health crisis among young people is looming, and a large part of it is online. Cheddar News speaks with digital policy expert Karen Kornbluh on the issue.
Back in 2010, several large companies pledged to work towards stopping deforestation by 2020. Companies like Nestle and Carrefour even went further to say that they would eliminate deforestation from their supply chains altogether. However, fast forward to 2020, many of these companies have failed to reach that goal. Associate Director of Forest at the CDP Nadia Bishai, joined Cheddar to discuss more.
A new study by Pfizer-BioNTech found that a third dose of their COVID-19 vaccine is effective against the emerging omicron variant. The pharmaceutical giants also look to manufacture a vaccine specific to the omicron variant by March 2022.
